VIM and non-small cell lung carcinoma: In a non-small cell lung cancer (NSCLC) model induced by LSL-KrasG12D/Tp53fl/fl, whole-body knockout of vimentin attenuated cancer-associated cachexia symptoms, inhibited tumour growth, and led to improved survival [101].